Market Research Reports By Publisher

Datamonitor

1 2 3 4 5 6 7 8 9 10 Next

Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents
Published by Datamonitor in June 2010
IntroductionIn 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent ex...(more)

Novartis AG: PharmaVitae Profile
Published by Datamonitor in June 2010
IntroductionThis analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forec...(more)

GlaxoSmithKline plc: PharmaVitae Profile
Published by Datamonitor in June 2010
IntroductionThis analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales fo...(more)

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
Published by Datamonitor in June 2010
IntroductionThe UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total...(more)

Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?
Published by Datamonitor in June 2010
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market w...(more)

Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline
Published by Datamonitor in June 2010
Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6...(more)

Osteoporosis Market Forecast
Published by Datamonitor in June 2010
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market w...(more)

Commercial Insight: Osteoporosis – Market players maximize revenue growth before the next challenging phase
Published by Datamonitor in June 2010
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market w...(more)

Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures
Published by Datamonitor in May 2010
The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metastatic disease are poorly served by current drugs, with very few approved treatment options and no widely accepted standard of care. A significant unmet need th...(more)

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
Published by Datamonitor in May 2010
Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle cl...(more)

1 2 3 4 5 6 7 8 9 10 Next

Home | About | Market Research by Sector |
Pharmaceutical Research Firms | Pharmaceutical Suppliers Directory | faq | Privacy | Terms
Site Contents